NMS · Biotechnology

BioCryst Pharmaceuticals, Inc. (BCRX) Stock

$9.75 +4.39% NMS: BCRX Healthcare

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics.

Valuation

MetricValue
Price$9.75
Market Cap$2.48B
P/E Ratio-5.40
P/B Ratio-4.09
P/S Ratio2.68
EPS (TTM)$0.00
52-Week High$11.22
52-Week Low$6.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE123.57%
ROA-98.48%
ROCE-141.60%
Gross Margin38.97%
Operating Margin38.97%
Net Margin-51.71%
Debt/Equity-1.55
Current Ratio2.06

Annual Financials (USD)

Metric20212022202320242025
Revenue$157.0M$271.0M$331.0M$451.0M$875.0M
Operating Profit$-178.0M$-148.0M$-104.0M$-3.0M$341.0M
Net Profit$-184.0M$-247.0M$-227.0M$-89.0M$264.0M
EPS$-1.03$-1.33$-1.18$-0.43$1.21
Op Margin-113.1%-54.8%-31.3%-0.6%39.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$588.0M$550.0M$517.0M$490.0M$514.0M
Total Liabilities$695.0M$845.0M$972.0M$966.0M$633.0M
Cash$504.0M$305.0M$111.0M$105.0M$90.0M
Borrowings$593.0M$741.0M$825.0M$841.0M$439.0M

Latest News

BioCryst Appoints David W. Jenkins as Chief Scientific Officer GlobeNewswire · Jul 15, 2026 Wall Street Analysts Think BioCryst (BCRX) Could Surge 117.96%: Read This Before Placing a Bet Zacks · Jul 14, 2026 BioCryst (BCRX) Stock Looks Below Fair Value As Caution Lingers Simply Wall St. · Jul 9, 2026 Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs? Stocktwits · Jul 9, 2026 BioCryst Pharmaceuticals (BCRX) Ends Internal Discovery And Closes Birmingham Facility Simply Wall St. · Jul 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-142.0M$-162.0M$-95.0M$-52.0M$330.0M
Investing Cash Flow$13.0M$-130.0M$-134.0M$51.0M$-16.0M
Financing Cash Flow$16.0M$15.0M$-26.0M$-4.0M$-9.0M
Net Cash Flow$233.0M$-201.0M$-194.0M$-6.0M$-103.0M
Free Cash Flow$-145.0M$-163.0M$-97.0M$-53.0M$327.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA8.27
FCF Yield13.20%
Quick Ratio2.04
Interest Coverage4.32
Return 1Y9.94%
Return 3Y27.31%
Return 5Y-44.90%

Ownership

Insiders Held1.20%
Institutions Held100.25%
Institutions Float Held101.47%
Institutional HolderSharesReport Date
Blackrock Inc.22,650,9882026-03-31
RA Capital Management, L.P.15,827,1862026-03-31
Deerfield Management Company, L.P15,038,0002026-03-31
State Street Corporation12,208,3602026-03-31
Vanguard Portfolio Management LLC11,244,6252026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARDX $5.09 +0.49% 11.04 $1.26B 0.00%
MAZE $27.88 -2.82% -8.11 $1.54B 0.00%
NTLA $10.89 +2.06% -3.55 $1.22B 0.00%
PHVS $32.62 -3.05% -9.75 $2.28B 0.00%
STOK $32.19 +0.81% -10.47 $2.08B 0.00%

About BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.

BioCryst Pharmaceuticals, Inc. (BCRX) stock trades at $9.75 with a market capitalization of $2.48B. The stock is valued at a price-to-earnings (P/E) ratio of -5.40, price-to-book of -4.09, price-to-sales of 2.68. Over the past 52 weeks the stock has ranged between $6.00 and $11.22, and currently trades 13.1% below its 52-week high.

On profitability, BioCryst Pharmaceuticals, Inc. generates a return on equity (ROE) of 123.57% — well above the market average, a sign of a high-quality business, return on capital employed of -141.60%, an operating margin of 38.97%, a net profit margin of -51.71%.

Official website: www.biocryst.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides